Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING

Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study

NCT06234488 · View on ClinicalTrials.gov ↗

Study Summary

There is no granular retrospective data on breast cancer in transgender and gender-diverse (TGD) persons from a contemporary and diverse American cohort. The purpose of this investigation is to aggregate data from multiple institutions to describe the risk, diagnosis, management, and outcomes of TGD persons with breast cancer in effort to identify opportunities for future intervention studies to eliminate breast cancer disparities for this population.

Study Locations (20)

Illinois

  • Northwestern Medicine — Chicago
  • Rush University Medical Center — Chicago
  • NorthShore University Health System — Evanston

Massachusetts

  • Massachusetts General Hospital — Boston
  • Birgham and Women's Hospital — Boston
  • Boston University (Boston U) — Boston

California

  • University of Southern California/Los Angeles (USC/LA County) — Los Angeles
  • University of California San Francisco (UCSF) — San Francisco

Florida

  • Mayo Clinic — Jacksonville
  • Moffitt Cancer Center (MCC) — Tampa

New York

  • New York University (NYU) — New York
  • University of Rochester — Rochester

Colorado

  • University of Colorado Anschutz Medical Campus (CU Anschutz) — Aurora

District of Columbia

  • MedStar Georgetown University Hospital (MGUH) — Washington D.C.

Michigan

  • University of Michigan — Ann Arbor

Trial Details

FieldValue
Enrollment Target 125 participants
Start Date 2023-12-08
Est. Completion 2026-08-30

Sponsor

Medical College of Wisconsin

614 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06234488

The ClinicalTrials.gov registry entry for NCT06234488 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical College of Wisconsin, which has 614 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 7 conditions, with Breast Cancer appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06234488 reports 20 study locations spanning 13 distinct geographic areas — top geographies include Illinois, Massachusetts, California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06234488 about?

NCT06234488 is a clinical study titled "Multi-Institutional Transgender & Gender-Diverse Breast Cancer Study". There is no granular retrospective data on breast cancer in transgender and gender-diverse (TGD) persons from a contemporary and diverse American cohort. The purpose of this investigation is to aggregate data from multiple institutions to describe the risk, diagnosis, management, and outcomes of TGD...

What is the current status of trial NCT06234488?

This trial is currently active not recruiting. The enrollment target is 125 participants. The study started on 2023-12-08. Estimated completion is 2026-08-30.

What conditions does trial NCT06234488 study?

This clinical trial studies the following conditions: Breast Cancer, Breast Neoplasms, Breast Adenocarcinoma, Breast Cancer Stage IV, Breast Cancer Invasive. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

Who is sponsoring clinical trial NCT06234488?

This trial is sponsored by Medical College of Wisconsin, which has 614 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06234488 being conducted?

This trial has 20 study locations across California, Colorado, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial